Kameel D. Farag - 16 Dec 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Reporting relationship: Interim CFO
Issuer ticker: AKTX
Reported as of: 16 Dec 2025
Net transaction value: +$9,999
SEC form: 4
Accepted by SEC: 18 Dec 2025, 21:57:09 UTC
Prior SEC filing: 04 Nov 2025
Next SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Abizer Gaslightwala, as Attorney-in-Fact

Key filing fact

Kameel D. Farag filed Form 4 for Akari Therapeutics Plc (AKTX) on 18 Dec 2025.

Key facts

This page summarizes Kameel D. Farag's Form 4 filing for Akari Therapeutics Plc (AKTX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 18 Dec 2025, 21:57.

Change

Previous filing in this sequence was filed on 04 Nov 2025.
Current net transaction value: +$9,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002093620 Primary reporting owner

Farag Kameel D.

Relationship: Interim CFO
Address: C/O AKARI THERAPEUTICS PLC, 401 EAST JACKSON STREET, SUITE 3300, TAMPA
Signature: /s/ Abizer Gaslightwala, as Attorney-in-Fact
Signature date: 18 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKTX transaction Derivative

Warrants to purchase American Depositary Shares ("ADRs")

Purchase

Transaction value
Shares: +24,745
Change %
Price
Shares after: 24,745
Date: 16 Dec 2025
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 24,745
Exercise price: $0.3883
Footnotes: F1, F2, F3, F4

AKTX transaction Derivative

Pre-Funded Warrants to purchase ADRs

Purchase

Transaction value: $9,999
Shares: +24,745
Change %
Price: $0.4041
Shares after: 24,745
Date: 16 Dec 2025
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 24,745
Exercise price: $0.000000
Footnotes: F1, F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.

Footnote F2

On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 24,745 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 24,745 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

Footnote F3

The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised.

Footnote F4

The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.

Footnote F5

Conversion Exercise Price of Security is $0.00001